Company Filing History:
Years Active: 2017-2021
Title: Andrew Leger: Innovator in Antisense Oligonucleotide Technology
Introduction
Andrew Leger is a prominent inventor based in Boston, MA (US), known for his contributions to the field of antisense oligonucleotide technology. With a total of 3 patents, he has made significant strides in developing innovative solutions for genetic disorders.
Latest Patents
One of his latest patents is titled "Multiple oligonucleotide moieties on peptide carrier." This patent focuses on antisense oligonucleotides (AONs), particularly phosphorodiamidate morpholino oligonucleotides (PMOs). The invention involves the conjugation of multiple PMOs to cationic cell-penetrating peptides (CPPs) to enhance the uptake of PMOs into skeletal and cardiac muscle cells. Another notable patent is "Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy." This patent provides peptide-linked morpholino (PPMO) antisense oligonucleotides that target the poly CUG repeat tract in the 3' untranslated region of the gene encoding dystrophia myotonica-protein kinase (DMPK). It also outlines methods for systemic administration of these oligonucleotides for the treatment of myotonic dystrophy type I (DM1).
Career Highlights
Throughout his career, Andrew Leger has worked with leading companies in the biotechnology sector, including Genzyme Corporation and Ionis Pharmaceuticals, Inc. His work has been instrumental in advancing therapeutic approaches for genetic diseases.
Collaborations
Andrew has collaborated with notable professionals in his field, including Bruce M Wentworth and Seng H Cheng. These collaborations have further enriched his research and development efforts.
Conclusion
Andrew Leger is a distinguished inventor whose work in antisense oligonucleotide technology has the potential to transform treatments for genetic disorders. His innovative patents and collaborations highlight his commitment to advancing medical science.